Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1661-3805|11|6|418-422

ISSN： 1661-3791

Source： Breast Care, Vol.11, Iss.6, 2016-11, pp. : 418-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 392-397

Karger

Access to resources Recommend Favorite

Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

By  

Breast Care, Vol. 2, Iss. 4, 2007-08 ,pp. : 227-233

Karger

Access to resources Recommend Favorite

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

By  

Breast Care, Vol. 11, Iss. 2, 2016-02 ,pp. : 133-138

Karger

Access to resources Recommend Favorite

HER2 Testing in Breast Cancer: Opportunities and Challenges

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 69-76

Karger

Access to resources Recommend Favorite